ALLG trials at prestigious international conferences

Two ALLG clinical trials, ALL08 BLAM and NHL29 IRIC have been accepted as abstracts with poster presentations at the prestigious European Hematology Association (EHA) Hybrid Congress June 8 – 11, 2023, Frankfurt, Germany. Abstracts accepted to the EHA are considered amongst the world’s best.

ALL08 BLAM is the first upfront study in older adults with Acute Lymphoblastic Leukaemia undertaken by the ALLG, utilising the combination of chemotherapy and immunotherapy in an attempt to improve disease response and minimize side-effects.

The ALL08 BLAM study recruited 30 patients across 10 Australian sites and has already gone on to inform future trials exploring reduced toxicity approaches to the management of Ph negative B-ALL in older patients. Congratulations to the Chief Investigators, Associate Professor Shaun Fleming, Prof Andrew Wei, Dr Ashish Bajel and A/Prof Matthew Greenwood.

A/Prof Fleming will present ALL08 BLAM at the EHA Congress Poster Session 6pm Friday 9 June, 2023 CEST. 

NHL29 IRIC study aimed to improve survival and minimise side-effects with a novel therapy-ibrutinib-with chemotherapy in elderly patients newly diagnosed with diffuse large B cell lymphoma, aged 75 or older. This is an important consideration, as older patients represent a substantial proportion of patients with this type of common lymphoma and they often have a different disease biology and tolerance of full dose chemotherapy. 80 patients were recruited across 20 sites in Australia. Congratulations to the Chief Investigators, Professor Judith Trotman and Dr Emma Verner.

Dr Verner presents NHL29 IRIC at the EHA Congress Poster Session 6pm Friday 9 June, 2023 CEST

The NHL29 IRIC trial has also been accepted to another prestigious event for the scientific community, the International Conference on Malignant Lymphoma (ICML). Organised by the Foundation for the Institute of Oncology Research (IOR), in partnership with the American Association for Cancer Research (AACR) and in collaboration with the European School of Oncology (ESO). The ICML has led to significant advancements in the field of lymphomas since its inception.

Dr Verner presents NHL29 IRIC at the ICML Lugano Poster Session 12.30pm Thursday 15 June, 2023 CEST.

These trial presentations at prestigious conferences are testament to the mentorship opportunities that the ALLG Membership provides to junior doctors about clinical trials, publications and presentations that increase professional knowledge and experience. Learn more about ALLG Membership.

The ALL08 BLAM has been presented at previous conferences: Blood 2022 and 2021, ASH 2021 and 2019.

The NHL29 trial has also been presented at previous conferences: ICML 2019; EHA 2019; Blood 2019 and 2022; and ASH 2021. The trial was also presented in ALLG correlative studies [that test for a relationship between a condition and a potential causal factor of the condition]. Dr Sewa Rijal presented at Blood 2022 and Dr Kate Phillips presented at International Society for Laboratory Haematology 2022.

You can read more about these clinical trials and others in the ALLG’s Research Report publication, available to download from the ALLG home page.

You can also learn more about the ALLG’s five decades of impact in clinical trials for blood cancer here.

About the ALLG

For five decades now, our cooperative group, the ALLG has been bringing together blood cancer experts from across Australia and New Zealand to volunteer their time and run clinical trials to change the way blood cancers – leukaemia, lymphoma and myeloma, – are treated. Our not-for-profit has contributed to what are now standard treatments for some blood cancers and continues to drive change for greater access to new and more effective therapies for patients.

If you are interested in participating in a clinical trial, speak with you doctor and visit ALLG’s Frequently Asked Questions about participating in a clinical trial and learn more here about getting involved in clinical trial research.

You can sign up here to receive our quarterly community newsletter, ALLG News, for clinical trial news and more. You can learn more about ALLG News and access current and past editions to read online here.

Follow us on Twitter, Linkedin and Facebook.

Did you know that the ALLG is registered charity?

100% of donations go to our clinical trials’ program. Find out some of the ways you can support this mission for better treatments, better lives for patients with blood cancer. Learn more here.